Changes to '113 trial...added 5th Cohort for brain mets...
Trial size increased from 130 to 175.
Narrowed cohort #3 to EGFR with T790M.
Added new cohort #5: NSCLC patients whose tumors exhibit ALK rearrangements and who have active, measurable brain metastases: -Either crizotinib naive or resistant; -Have at least one measurable brain lesion -Previously untreated brain metastases with radiologically documented new or progressing brain lesions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.